Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets

Rhea-AI Summary

Nektar Therapeutics (Nasdaq: NKTR) has announced that it will release its financial results for the second quarter of 2024 on Thursday, August 8, 2024, after the close of U.S.-based financial markets. The company's President and CEO, Howard Robin, will host a conference call at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time to review the results.

Investors and interested parties can access the press release and live audio-only webcast of the conference call through a link on the Home Page and Investors section of Nektar's website. The web broadcast will be available for replay until September 8, 2024. To participate in the conference call, pre-registration is required through the Nektar Earnings Call Registration link.

SAN FRANCISCO, Aug. 1, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2024 on Thursday, August 8, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through September 8, 2024.

To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contacts:

For Investors:

Vivian Wu of Nektar Therapeutics
(628) 895-0661

For Media:

David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-second-quarter-2024-on-thursday-august-8-2024-after-close-of-us-based-financial-markets-302212901.html

SOURCE Nektar Therapeutics

FAQ

When will Nektar Therapeutics (NKTR) release its Q2 2024 financial results?

Nektar Therapeutics (NKTR) will release its Q2 2024 financial results on Thursday, August 8, 2024, after the close of U.S.-based financial markets.

How can I access Nektar's (NKTR) Q2 2024 earnings conference call?

You can access Nektar's Q2 2024 earnings conference call by pre-registering through the Nektar Earnings Call Registration link. The call will be held on August 8, 2024, at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

Where can I find the webcast replay of Nektar's (NKTR) Q2 2024 earnings call?

The webcast replay of Nektar's Q2 2024 earnings call will be available on the company's website at http://ir.nektar.com/ until September 8, 2024.

Who will host Nektar Therapeutics' (NKTR) Q2 2024 earnings call?

Howard Robin, President and Chief Executive Officer of Nektar Therapeutics, will host the Q2 2024 earnings call.